Scenarios that move ROIV

Roivant Sciences Ltd. - Common Shares

Scenarios that move ROIV: 2 analyses, 0 positive, 2 negative.

  1. · argenx meets primary endpoint in Phase II celiac disease study — ▼ · impact -24 · confidence low · horizon immediate
  2. · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -8 · confidence low · horizon quarters

All scenarios · Run a scenario · Pricing